In a child with traumatic hemorrhage occurring within three hours and no contraindications (active intravascular clotting, seizure disorder, severe renal impairment), what are the indications, dosing regimen, and monitoring recommendations for tranexamic acid?

Tranexamic Acid for Pediatric Trauma

In children with traumatic hemorrhage, administer tranexamic acid 15 mg/kg IV over 10 minutes (maximum 1 g) as soon as possible and within 3 hours of injury, followed by a maintenance infusion of 2 mg/kg/hour for 8 hours. 1

Indications

• Pediatric trauma patients with active bleeding or at risk of significant hemorrhage should receive TXA as part of massive hemorrhage protocols. 2

• The drug is indicated for children with hemodynamic instability (hypotension, tachycardia) or clinically significant blood loss from traumatic injury. 2

• TXA should be given regardless of the specific anatomic source of bleeding—whether from solid organ injury, vascular trauma, or other hemorrhagic injuries. 2

Dosing Regimen

Loading Dose

• Administer 15 mg/kg IV over 10 minutes (maximum dose 1 g). 1, 2

• For children older than 12 years, use the adult loading dose of 1 g IV over 10 minutes. 2

• The loading dose should be prescribed in volume (mL) rather than unit doses, with sensible rounding to facilitate bedside preparation. 2

Maintenance Infusion

• Follow the loading dose with a continuous infusion of 2 mg/kg/hour for 8 hours. 1, 2

• For children older than 12 years, use the standard adult maintenance regimen of 1 g infused over 8 hours. 2

Practical Administration Considerations

• Current U.S. practice data show that 68% of pediatric trauma centers using TXA employ the 15 mg/kg loading dose, with 87% following with an infusion (most commonly 2 mg/kg/hour × 8 hours). 3

• The median time from injury to first dose in trauma trials is approximately 79 minutes (IQR 55-112 minutes). 4

Critical Timing Window

• TXA must be administered within 3 hours of injury for benefit; efficacy decreases by 10% for every 15-minute delay. 1, 2, 5

• The optimal therapeutic window may be even narrower—within 90 minutes of injury—based on recent adult trauma data showing maximum mortality reduction when given within this timeframe. 4

• Administration after 3 hours provides no benefit and may paradoxically increase the risk of death from bleeding. 1, 5

• Earlier administration is always better: give TXA as soon as traumatic hemorrhage is identified, ideally in the prehospital setting or immediately upon emergency department arrival. 2, 5

Pre-Administration Assessment

• Before TXA administration, rapidly assess for:

  • Active bleeding or hemodynamic instability (hypotension, tachycardia) 2
  • Estimated blood loss and ongoing hemorrhage 2
  • Time from injury (must be <3 hours) 2
  • Contraindications: active intravascular clotting, known thromboembolic event, severe renal impairment, or seizure disorder 2

• Do not delay TXA administration waiting for laboratory results or imaging—give empirically based on clinical assessment of significant hemorrhage. 2

Monitoring Recommendations

• Ongoing monitoring should focus on signs of continued hemorrhage and the patient's response to resuscitation efforts. 2

• Monitor for:

  • Hemodynamic parameters (blood pressure, heart rate, perfusion) 2
  • Ongoing blood loss (clinical assessment, serial hemoglobin if time permits) 2
  • Response to blood product resuscitation 2
  • Adverse effects, particularly seizures with higher doses 5, 6

• Children receiving rapid blood product administration are especially vulnerable to hypothermia and electrolyte disturbances; vigilant monitoring for these complications is essential. 1, 2

Renal Impairment Considerations

• In patients with severe renal impairment, dose adjustments are required because TXA is approximately 90% renally excreted and can accumulate, increasing the risk of neurotoxicity. 2

• Assess renal function when possible, though this should not delay initial administration in life-threatening hemorrhage within the 3-hour window. 2

Integration with Hemorrhage Control Protocols

Damage Control Resuscitation Principles

• TXA is an adjunctive therapy; definitive hemorrhage control must still be pursued using temporary hemostatic measures (pressure, tourniquets) followed by surgical or interventional radiology intervention. 1, 2

• Ensure clinical treatment is constantly directed toward hemorrhage control—TXA does not replace the need for operative or endovascular bleeding control. 1

Blood Product Resuscitation

• Empiric blood product resuscitation should be initiated concurrently with TXA: 2

  • Fresh frozen plasma: 10-15 mL/kg 1, 2
  • Platelets: 10-20 mL/kg 2
  • Cryoprecipitate: 5-10 mL/kg 2

• During active hemorrhage, administer RBC and FFP in a 1:1 ratio to replace fluid volume. 1

• Once hemorrhage control is achieved, blood components should be administered as guided by laboratory or point-of-care testing. 1

Hemodynamic Management

• Maintain permissive hypotension (target systolic 80-100 mmHg) until hemorrhage control is achieved, except in cases of traumatic brain injury or spinal cord injury. 2

• Do not attempt to normalize blood pressure during active hemorrhage with volume resuscitation alone. 1

• Avoid vasopressors during active hemorrhage. 1

Fluid Management

• Avoid crystalloid and colloid administration during uncontrolled hemorrhage; reserve clear fluids only for profound hypotension when blood products are unavailable. 1, 2

Safety Profile

• No increase in thromboembolic events has been demonstrated in pediatric trauma populations receiving TXA. 2

• The TIC-TOC pilot trial evaluated two dosing regimens (15 mg/kg and 30 mg/kg bolus doses) in 31 severely injured children without identifying statistically significant differences in adverse events between groups. 6

• Higher doses may increase seizure risk, particularly with the 30 mg/kg bolus regimen. 5, 6

• The standard 15 mg/kg loading dose followed by 2 mg/kg/hour infusion represents the optimal balance of efficacy and safety. 1, 2, 3

Common Pitfalls to Avoid

• Do not wait beyond 3 hours from injury to administer TXA—this eliminates benefit and may cause harm. 1, 2

• Do not delay TXA administration for laboratory confirmation of coagulopathy or hyperfibrinolysis—give empirically based on clinical hemorrhage. 2, 3

• Do not use TXA as a substitute for definitive hemorrhage control—surgical or interventional radiology intervention remains essential. 1, 2

• Do not forget to adjust dosing in severe renal impairment to prevent drug accumulation and neurotoxicity. 2

• Do not administer large volumes of crystalloids during uncontrolled hemorrhage, which dilutes coagulation factors and worsens outcomes. 1, 2

• Remember that children have an estimated blood volume of 70 mL/kg (up to 100 mL/kg in newborns), requiring age-appropriate vascular access devices and blood administration rates. 1